Lithuania vs Naoero: The number of people with susceptibility test result for rifampicin
Lithuania
100
in 2021
Naoero
100
in 2021
Lithuania rank
2nd
Naoero rank
2nd
The number of people with susceptibility test result for rifampicin over time
- Lithuania
- Naoero
How they compare
Lithuania currently reports 100 against 100 in Naoero, a difference of 0.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Lithuania ahead.
Lithuania ranks 2nd and Naoero ranks 2nd of 146 countries.
Lithuania has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Lithuania | Naoero | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 100 | 0 | 100 | Lithuania |
| 2020s | 100 | 50 | 50 | Lithuania |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Lithuania or Naoero?
- Lithuania, at 100 against 100 in Naoero as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Lithuania and Naoero?
- 0, with Lithuania ahead.
- How many years of comparable data are there for Lithuania and Naoero?
- 5 years are reported by both, from 2017 to 2021.
- How do Lithuania and Naoero rank globally for the number of people with susceptibility test result for rifampicin?
- Lithuania ranks 2nd and Naoero ranks 2nd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.